NASDAQ NMS - GLOBAL MARKET · LSTA
+0.95% · +$0.0100 · Vol 146.9K
After hours · updated 17:42:44 ET
Lisata Therapeutics Inc

Lisata Therapeutics Inc

Biotechnology
$1.06
Card
Relationship Map

Follow $LSTA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $LSTA by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
LSTA
Lisata Therapeutics Inc
Tue Oct 13 · session closed · Markets closed · resumes Wed 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

44/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →or $250/yr
Cancel anytime · or Reserve · $79/moor $790/yr
Confidence: HIGH · 6 of 6 factors measured · Tue Oct 13 · session closed · Markets closed · resumes Wed 9:30 ET
Share on X →
AI Analysis
Sovereign

Why is LSTA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Lisata Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
1999
Employees
21
Country
US

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.10
Day high
$1.15
Day low
$0.9900
Previous close
$1.05
52W high
$5.04
-78.97% from high
52W low
$0.9900
2% of range
Market cap
$11.3M
EPS
$-1.1436
Beta
-0.55
Shares out
10.8M
Volume
146.9K
0.58× rel vol
Avg volume
252.9K
VWAP
$1.07
Price history computed in-house
1W
-12.40%
1M
-34.97%
3M
-71.73%
1Y
-56.38%
YTD
-43.01%
SMA 50 $1.42 · below
SMA 200 $3.05 · below
52W position 2%

LSTA overview

Veridion Score
44
Registered · 2026-10-13
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around LSTA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Public disclosures

Congress activity in LSTA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

LSTA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LSTA in this window.
Lobbying spend

LSTA lobbying filings, year to date.

Registered lobbying filings matched to Lisata Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LSTA in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for LSTA.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.